Scientists project that by 2026 the results of clinical trials being conducted in 25 countries, including Spain, will be ...

Gilead Sciences, Inc. today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated ...

On February 25, 2025, the Company announced positive 12-week data from the sixth cohort of the ongoing RESOLVE trial in patients with eosinophilic esophagitis (“EoE”) noting no adverse events and ...

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third ...

GreenShield proudly announces the launch of GreenShield Ventures ? an innovation hub dedicated to developing new products and services to revolutionize health outcomes for all ...

Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 finan ...

Diagnosed with allergies to multiple foods – including peanuts, eggs, cashews and hazelnuts – Cole faced an anxious childhood ...

Patterson, 50, is accused of deliberately poisoning a beef wellington dish intending to kill four members of her estranged ...

With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the ...